Trial Profile
Investigating whether and how specific 18-FAV-1451 binding in ascending Braak stages relates to regional atrophy patterns across the Alzheimer's disease (AD) spectrum
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2018
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- 03 Oct 2018 New trial record